Epilepsy Trial, Recruiting NCT07531511 Sponsor: UCB Biopharma SRL Condition: Epilepsy
Back to Epilepsy

Epilepsy Trial, Recruiting

NCT07531511
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a condition called SLC6A1-NDD, which involves a specific gene mutation, and who experience epilepsy, developmental delays, autism spectrum disorder, or intellectual disability as part of that condition.
  • People who are 17 years old or younger at the time of signing up for the trial.
  • People who are under 18 years old and have a parent or legal guardian who is able to provide consent on their behalf (and where appropriate, the child themselves may also be asked to agree to participate).
  • People whose caregivers are willing and able to follow the study requirements, including keeping a diary and attending scheduled visits.

Who may not be able to join:

  • People whose caregivers are unable to attend the required follow-up visits.
  • People who have another diagnosed condition — including one caused by a different gene — that is known to cause epilepsy or neurodevelopmental disorders.
  • People who are currently taking another experimental treatment (other than a specific medication called 4-phenylbutyrate), or who have taken an experimental treatment within the past 30 days or within a certain timeframe based on how long that treatment stays in the body, whichever is longer (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: UCB Cares, 001 844 599 2273 (UCB)

Phone: +18445992273

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
UCB Biopharma SRL
Registry
ClinicalTrials.gov
Start date
21 July 2026
Est. completion
25 May 2029

Where this trial is recruiting

🇫🇷 France 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Seizure frequency by type (countable seizures per 28 days) by visit as compared to Baseline; Seizure free days per 28 days by visit as compared to Baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov